GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • April 21- Amgen Inc reported higher first-quarter earnings on Tuesday, driven by price increases for its biggest-selling drugs, as well as lower spending on research and development. Amgen raised its full-year outlook for adjusted earnings per share to between $9.35 and $9.65 from a previous range of $9.05 to $9.40. Amgen said sales of rheumatoid arthritis...

  • A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed, mostly failing to hold momentum from Monday, as investors reacted to individual earnings reports of major companies.

  • Wall Street optimistic on bumper earnings day Tuesday, 21 Apr 2015 | 8:08 AM ET
    Yahoo President and CEO Marissa Mayer delivers a keynote address at the 2014 International CES in Las Vegas.

    U.S. stock index futures indicated a higher open on Tuesday, ahead of a spate of major earnings and as oil futures for May were set to expire.

  • Earnings next test for stocks after market wipeout Monday, 20 Apr 2015 | 5:52 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • Earnings next test for stocks after market wipeout Friday, 17 Apr 2015 | 4:29 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks could chop around and rack up more losses in the week ahead, with the next wave of corporate earnings reports.

  • April 15- U.S. health regulators on Wednesday approved Amgen Inc's Corlanor to treat patients with chronic heart failure, giving the world's largest biotechnology company its first cardiovascular product. RBC Capital Markets analyst Michael Yee said that long term Corlanor could become a $500 million a year drug for Amgen. Amgen shares rose 1.3 percent in...

  • After-hours buzz: Netflix, General Motors & more Wednesday, 15 Apr 2015 | 5:08 PM ET
    Traders work the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's after-hours buzz: Netflix, General Motors & more

  • 5 biotech bets: Trading a surging sector Thursday, 9 Apr 2015 | 7:36 PM ET
    Amgen

    CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.

  • Goldman's top picks Tuesday, 7 Apr 2015 | 2:11 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.

  • Cramer: 4 horsemen of biotech & semis are back Sunday, 29 Mar 2015 | 1:33 PM ET
    A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange, July 18, 2014.

    Jim Cramer saw the proximate cause of this week's decline to these stocks. Now they're showing signs of life.

  • Cramer Remix: A bottom in biotech? Hardly Friday, 27 Mar 2015 | 7:23 PM ET
    Jim Cramer on Mad Money.

    “Mad Money” host Jim Cramer sees a pulse back in biotechs. Time to jump in?

  • Biotech woes: Deja vu all over again Thursday, 26 Mar 2015 | 12:59 PM ET
    Biotech

    For biotech watchers, it's deja vu all over again. Through Wednesday, the Nasdaq Biotechnology Index dropped 6.9 percent since the close March 20.

  • Trading the selloff: 8 stocks to buy Wednesday, 25 Mar 2015 | 6:50 PM ET
    A file photo of a FedEx truck

    "Fast Money" traders discussed how to play Wednesday's selloff in biotech, transportation and technology names.

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Biogen takes aim at Alzheimer's, ALS drugs Monday, 23 Mar 2015 | 6:48 AM ET
    A multiple sclerosis drug manufactured at the Biogen Idec manufacturing plant in Cambridge, Mass.

    Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions.

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • 6 trades on surging biotech sector Friday, 20 Mar 2015 | 6:39 PM ET

    Big-name biotech stocks have been on a tear, but some "Fast Money" traders warned the run may not continue.

  • Cramer: Snap up this incredible opportunity Thursday, 19 Mar 2015 | 6:22 PM ET
    Lab technician handling test tubes

    Jim Cramer can't believe how Esperion Therapeutics stock has shot through the roof! Can it keep going?

  • NEW YORK, March 19- A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The judge denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat drug.

  • March 16- U.S. stocks rallied on Monday as the U.S. dollar eased back from its recent peak and worries eased about the timing of a Federal Reserve interest rate hike. The S&P healthcare sector led gains in the S&P 500. It jumped 2.2 percent, helped by a 5.7 percent price increase in shares of Amgen to $163.03, following promising data in studies of a new class of...